Compare Rivian Automotive, Inc. (RIVN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs BIO-TECHNE Corp — how do they compare? Rivian Automotive, Inc. trades at $14.34 (market cap $20.76B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Rivian Automotive, Inc. is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rivian Automotive, Inc. for 61 Days and BIO-TECHNE Corp for 63 Days on average.
| RIVN | TECH | |
|---|---|---|
Market Cap | $20.76B | $11.37B |
Volume | 21,976,075 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $72.61 |
52-Week Low | $12.50 | $43.31 |
Typical Hold Time | 61 Days | 63 Days |
Enterprise Value | $20.81B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian (RIVN) trades at $14.33, down 1.24% on the day, amid bearish technical signals and ongoing financial losses. The company reported record Q3 2026 deliveries of 19,248 vehicles, beating estimates, but maintained its full-year guidance, disappointing investors seeking an upward revision. Revenue growth is improving, with 2025 revenue at $5.39 billion, yet net losses remain substantial at -$3.65 billion, reflecting high costs and scaling challenges in the competitive EV market.
The outlook is mixed: strong delivery growth and analyst buy ratings (48%) suggest potential, but persistent cash burn, negative margins, and technical bearishness pose significant risks. Investors should weigh the company's progress in scaling production and autonomy technology against its hefty losses and competitive pressures in the evolving electric vehicle industry.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
